Takeda files for once-daily pioglitazone combo in EU
This article was originally published in Scrip
Executive Summary
Takedahas made a filing with the EMEAthrough the centralised procedure for the European approval of a once-daily formulation of Competact, its pioglitazone plus metformin combination therapy for type 2 diabetes. A twice-daily version of the fixed-dose product, containing 15mg pioglitazone and 850mg metformin, is already on the market in several European countries, for patients insufficiently controlled on their maximum dose of metformin alone. A similar once-daily combination of the two ingredients was filed in the US (as ACTOplus met XR) in March 2006, but has yet to be approved.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.